Voyageur Pharmaceuticals Appoints Financial Veteran Virginia Alling to Board, Accelerating U.S. Market Strategy

Voyageur Pharmaceuticals Ltd. has appointed Virginia Alling as an independent director, subject to regulatory approval, marking the company's third recent board addition of Wall Street veterans to accelerate its U.S. market expansion strategy. Alling brings over 30 years of experience in corporate banking, capital markets, and strategic advisory for both privately held and publicly traded companies. As Senior Vice President & Managing Director at PNC Bank in East Brunswick, NJ, she manages a multi-billion-dollar portfolio of corporate clients in New Jersey and New York, including expertise in M&A, IPOs, ESOPs, leveraged finance, and revenue optimization.

Her appointment complements Voyageur's recent additions of Jeffrey J. Kraws and Christopher A. Van Buren to the board, creating a team with proven Wall Street acumen to facilitate the company's U.S. market expansion. Brent Willis, Voyageur's CEO, stated that Alling's track record in executing U.S. public offerings, revenue optimization, and cross-border financing will be instrumental in unlocking institutional U.S. investment and streamlining the company's U.S. market entry. The collective experience of these board members in revenue generation, IPO execution, and regulatory compliance is expected to support Voyageur's commercialization efforts, including FDA approvals for its barium contrast products and scaling of its Oklahoma iodine operations.

Voyageur, a Canadian public company trading under the symbol VM on the TSX Venture Exchange, is developing barium and iodine Active Pharmaceutical Ingredients for medical imaging contrast media. The company's strategic focus involves vertically integrating the barium and iodine contrast markets by producing its own materials. Voyageur owns a 100% interest in the Frances Creek barium sulphate project, which features a rare and exceptional grade mineral suitable for pharmaceutical applications. Currently, most pharmaceutical barium sulphate is synthetically produced, resulting in less effective imaging quality, and Voyageur believes its natural mineral will replace current synthetic products with higher quality imaging alternatives.

The company's business model involves partnering with established third-party GMP pharmaceutical manufacturers in Canada to validate its products with regulatory agencies worldwide. As Voyageur solidifies its market presence, it plans to transition into a high-margin domestic manufacturer of radiology drugs. The company's vision is to become the first vertically integrated company in the radiology contrast media drug market, controlling all primary input costs from raw material sourcing to final production. This approach, encapsulated in the motto "From the Earth to the Bottle," emphasizes Voyageur's commitment to responsible sourcing and manufacturing practices while ensuring quality and cost efficiency. Additional information about the company can be found at https://voyageurpharmaceuticals.ca.